Jacques Hugon
Overview
Explore the profile of Jacques Hugon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
2848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dumurgier J, Paquet C, Hugon J, Planche V, Gaubert S, Epelbaum S, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(3):100077.
PMID: 39880699
Background And Objectives: Primary care is often the first point of contact for patients with cognitive complaints, making initial cognitive screening an essential step to avoid delays in diagnosing Alzheimer's...
2.
Decaix T, Mouton-Liger F, Dumurgier J, Cognat E, Vrillon A, Hugon J, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100009.
PMID: 39800467
Background: The use of cerebrospinal (CSF) biomarkers in the diagnosis of Alzheimer's disease (AD) has been gaining interest in clinical practice. Although their usefulness has been demonstrated, their potential value...
3.
Saleh N, Blaise C, Daoudi A, Queneau M, Fard K, Dumurgier J, et al.
Int J Bipolar Disord
. 2024 Dec;
12(1):45.
PMID: 39739252
Background: Patients with bipolar disorder (BD) are at increased risk of dementia. The underlying mechanisms are debated. FDG-PET elucidates glucose metabolic reductions due to altered neuronal activity in the cerebral...
4.
Spencer P, Berntsson S, Buguet A, Butterfield P, Calne D, Calne S, et al.
J Neurol Sci
. 2024 Dec;
468():123340.
PMID: 39667295
While rising global rates of neurodegenerative disease encourage early diagnosis and therapeutic intervention to block clinical expression (secondary prevention), a more powerful approach is to identify and remove environmental factors...
5.
Lilamand M, Bouaziz-Amar E, Dumurgier J, Cognat E, Hourregue C, Mouton-Liger F, et al.
J Gerontol A Biol Sci Med Sci
. 2023 May;
78(7):1307-1308.
PMID: 37208788
No abstract available.
6.
Cognat E, Sabia S, Fayel A, Lilamand M, Handels R, Fascendini S, et al.
Am J Geriatr Psychiatry
. 2023 May;
31(8):633-639.
PMID: 37183097
Objective: Behavioral and psychological symptoms of dementia (BPSD) profiles vary depending on etiology in patients with mild-to-moderate BPSD. It is not known if similar differences exist in patients with severe...
7.
Hugon J
Eur J Neurol
. 2023 Feb;
30(5):1165-1166.
PMID: 36802122
Hundreds of millions of COVID cases have been reported so far and long-term lingering clinical symptoms are frequent and are called long COVID. Neurological signs including cognitive complaints are often...
8.
Gotze K, Vrillon A, Bouaziz-Amar E, Mouton-Liger F, Hugon J, Martinet M, et al.
Neurobiol Dis
. 2022 Dec;
176:105937.
PMID: 36462720
Objective: To explore the accuracy of plasma neurofilament light chain (NfL) as a biomarker for diagnosis and staging of cognitive impairment, in a large cohort with of previously diagnosed patients...
9.
Lilamand M, Bouaziz-Amar E, Dumurgier J, Cognat E, Hourregue C, Mouton-Liger F, et al.
J Gerontol A Biol Sci Med Sci
. 2022 Nov;
78(4):645-652.
PMID: 36441007
Background: Metabolic dysfunction and dysregulation of leptin signaling have been linked to Alzheimer's disease (AD)'s pathophysiology. The objectives of this study were to examine the associations between plasma leptin, cerebrospinal...
10.
Lilamand M, Clery J, Vrillon A, Mouton-Liger F, Cognat E, Gaubert S, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362275
Background: Alpha-synuclein, abnormally aggregated in Dementia with Lewy Bodies (DLB), could represent a potential biomarker to improve the differentiation between DLB and Alzheimer’s disease (AD). Our main objective was to...